Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending April 16, 2007. The report serves as a notification of transactions involving directors and persons discharging managerial responsibility, specifically regarding the Deferred Investment Award Plan.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on a specific share transaction event.
Material Changes
There are no material changes to the company's financial position or operations reported in this filing. The only reported activity is an increase in share interests for specific individuals following a dividend reinvestment.
Guidance, Outlook, and Risks
The filing contains no management commentary, future guidance, risk factors, or contingencies. It strictly details a transaction where Dr. M M Slaoui and other administrators increased their interest in Ordinary Shares at a price of GBP 14.20 per share. This transaction resulted from the reinvestment of the dividend paid to shareholders on April 12, 2007.
Key Facts for Investor Verification
- Transaction Date: April 16, 2007.
- Share Price: GBP 14.20 per share.
- Transaction Type: Reinvestment of dividend paid on April 12, 2007.
- Involved Parties: Administrators of the Deferred Investment Award Plan, including Dr. M M Slaoui.
- Regulatory Basis: Notification in accordance with Disclosure Rule 3.1.4R(1)(b).